CEROSTERIL

Informazioni principali

  • Nome commerciale:
  • CEROSTERIL SOLUZ CUT FL 250ML
  • Forma farmaceutica:
  • SOLUZIONE
  • Composizione:
  • "SOLUZIONE CUTANEA" FLACONE 250 ML
  • Classe:
  • C
  • Tipo di ricetta:
  • Senza obbligo di ricetta
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Farmaco allopatico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • CEROSTERIL SOLUZ CUT FL 250ML
    Italia
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Quaternary ammonium compounds

Altre informazioni

Status

  • Fonte:
  • AIFA - Agenzia Italiana del Farmaco
  • Numero dell'autorizzazione:
  • 032272015
  • Ultimo aggiornamento:
  • 09-08-2016

Foglio illustrativo

CATEGORIA FARMACOTERAPEUTICA

Disinfettante per uso topico dermatologico.

INDICAZIONI

Trattamento della cute lesa.

CONTROINDICAZIONI/EFFETTI SECONDARI

Ipersensibilita'ai componenti del prodotto.

POSOLOGIA

Applicare un impacco di garza sterile imbevuto di soluzione,

ripetendol'operazione 2-3 volte al di'.

INTERAZIONI

Evitare l'uso di altri detergenti ed antisettici.

EFFETTI INDESIDERATI

In qualche caso bruciore o irritazione.

17-8-2018

Animal Drug Under Fee Amendments Reauthorized Through September 2023 to Allow for FDA’s Continued Timely Review of Animal Drug Applications

Animal Drug Under Fee Amendments Reauthorized Through September 2023 to Allow for FDA’s Continued Timely Review of Animal Drug Applications

On 8/14/18, the Animal Drug and Animal Generic Drug User Fee Amendments of 2018 was signed into law to reauthorize ADUFA and AGDUFA. These programs help FDA maintain a predictable and timely animal drug review process, foster innovation, and expedite access to new therapies for animals.

FDA - U.S. Food and Drug Administration

2-8-2018

Minister Bruno Bruins bij start Skûtsjesilen

Minister Bruno Bruins bij start Skûtsjesilen

Minister van Sport Bruno Bruins bezoekt zaterdag 4 augustus de start van het jaarlijkse Sintrale Kommisje Skûtsjesilen (SKS) kampioenschap. Hierbij strijden 14 ‘Skûtsjes’ om de felbegeerde kampioenswimpel en de wisseltrofee: het Sulveren Skûtsje.  In totaal worden de komende twee weken 11 wedstrijden gezeild. De eerste wedstrijd start zaterdag op het Pikmeer bij Grou.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

25-7-2018

AMPI Recalls Limited Amount of Dry Whey Powder Because of Possible Health Risk

AMPI Recalls Limited Amount of Dry Whey Powder Because of Possible Health Risk

Associated Milk Producers Inc. (AMPI) of New Ulm, Minn., is recalling dry whey powder packaged in 50-pound and 25-kg bags that were produced at the cooperative’s Blair, Wis., dry whey plant from May 1-5, 2018; May 24-29, 2018; June 2-5, 2018; and June 7-14, 2018 due to the potential to be contaminated with Salmonella. This is a precautionary recall. All products shipped to the marketplace tested negative for Salmonella.

FDA - U.S. Food and Drug Administration

17-7-2018

Blokhuis kondigt grootschalige extra vaccinatie aan: Ruim half miljoen kinderen krijgen oproep

Blokhuis kondigt grootschalige extra vaccinatie aan: Ruim half miljoen kinderen krijgen oproep

Volgend jaar worden zo’n 650.000 kinderen extra opgeroepen om zich te laten inenten tegen de zeer ernstige infectieziekte meningokokken. Het gaat om kinderen die zijn geboren na 1 januari 2001 en voor mei 2004. Dat laat staatssecretaris Paul Blokhuis (VWS) weten in een brief aan de Tweede Kamer. Reden voor deze maatregel is dat in de afgelopen jaren een stijging te zien is van het aantal mensen dat de infectie meningokokken type W oploopt. Met deze extra vaccinatieronde moet die groei worden ingedamd. He...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

17-7-2018

ALDI Voluntarily Recalls AnnaSea Wasabi Ahi Poke Hawaiian Poke Kits and Limu Ahi Poke Hawaiian Poke Kits Due to Storage at Incorrect Temperature in Area Store

ALDI Voluntarily Recalls AnnaSea Wasabi Ahi Poke Hawaiian Poke Kits and Limu Ahi Poke Hawaiian Poke Kits Due to Storage at Incorrect Temperature in Area Store

Batavia, Ill. Uuly 14, 2018) -ALDI has voluntarily recalled AnnaSea Wasabi Ahi Poke Hawaiian Poke Kits and Limu Ahi Poke Hawaiian Poke Kits sold at one retail store location in North Carolina. While the products are required to remain at frozen temperatures to ensure safety, this store location displayed and sold the products from the cooler section. Because storing the products at temperatures above freezing prior to consumption can render the products unsafe for consumption, ALDI is recalling these items.

FDA - U.S. Food and Drug Administration

14-6-2018

Carenza Mabcampath (alemtuzumab) - modalità di richiesta d'importazione dall'estero (14/06/2018)

Carenza Mabcampath (alemtuzumab) - modalità di richiesta d'importazione dall'estero (14/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale “Mabcampath (alemtuzumab)", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

14-6-2018

Carenza FLUDARABINA - modalità di richiesta d'importazione dall'estero (14/06/2018)

Carenza FLUDARABINA - modalità di richiesta d'importazione dall'estero (14/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "FLUDARABINA", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

17-5-2018

Dollarama L.P. recalls Oball Rollin' Rainstick and Oball 2-IN-1 Roller

Dollarama L.P. recalls Oball Rollin' Rainstick and Oball 2-IN-1 Roller

If the ball structure were to be damaged, pieces of the ball could be pulled off therefore posing a choking hazard to young children. As of May 14, 2018, the company has received two incidents with no injuries in Canada.

Health Canada

14-8-2018

Nobivac LeuFel (Virbac)

Nobivac LeuFel (Virbac)

Nobivac LeuFel (Active substance: Feline leukaemia vaccine (inactivated)) - Centralised - 2-Monthly update - Commission Decision (2018)5535 of Tue, 14 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4778/WS/1282/1

Europe -DG Health and Food Safety

14-8-2018

Leucofeligen FeLV/RCP (Virbac)

Leucofeligen FeLV/RCP (Virbac)

Leucofeligen FeLV/RCP (Active substance: Not available) - Centralised - 2-Monthly update - Commission Decision (2018)5536 of Tue, 14 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/143/WS/1282/7

Europe -DG Health and Food Safety

10-8-2018

 Minutes of the PRAC meeting 11-14 June 2018

Minutes of the PRAC meeting 11-14 June 2018

Europe - EMA - European Medicines Agency

7-8-2018

Duloxetine Mylan (Generics [UK] Limited)

Duloxetine Mylan (Generics [UK] Limited)

Duloxetine Mylan (Active substance: Duloxetine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5417 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3981/T/14

Europe -DG Health and Food Safety

2-8-2018

EU/3/14/1351 (Kyowa Kirin Holdings B.V.)

EU/3/14/1351 (Kyowa Kirin Holdings B.V.)

EU/3/14/1351 (Active substance: Recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23) - Transfer of orphan designation - Commission Decision (2018)5289 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/133/14/T/02

Europe -DG Health and Food Safety

1-8-2018

IBRANCE (Pfizer Europe MA EEIG)

IBRANCE (Pfizer Europe MA EEIG)

IBRANCE (Active substance: palbociclib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5224 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3853/T/14

Europe -DG Health and Food Safety

31-7-2018

Join us for the Pediatric Medical Device Development public meeting Aug 13-14 to identify ways to increase the availability of medical devices for children.  https://go.usa.gov/xUvBD  #Pediatrics #medicaldevicepic.twitter.com/ZP3ImzNw2T

Join us for the Pediatric Medical Device Development public meeting Aug 13-14 to identify ways to increase the availability of medical devices for children. https://go.usa.gov/xUvBD  #Pediatrics #medicaldevicepic.twitter.com/ZP3ImzNw2T

Join us for the Pediatric Medical Device Development public meeting Aug 13-14 to identify ways to increase the availability of medical devices for children. https://go.usa.gov/xUvBD  #Pediatrics #medicaldevice pic.twitter.com/ZP3ImzNw2T

FDA - U.S. Food and Drug Administration

31-7-2018

On Aug 13-14, the #FDA is hosting the Pediatric Medical Device Development public meeting at the White Oak campus. Join us and participate in discussions around increasing medical device development for children. More info here:  https://go.usa.gov/xUvZm 

On Aug 13-14, the #FDA is hosting the Pediatric Medical Device Development public meeting at the White Oak campus. Join us and participate in discussions around increasing medical device development for children. More info here: https://go.usa.gov/xUvZm 

On Aug 13-14, the #FDA is hosting the Pediatric Medical Device Development public meeting at the White Oak campus. Join us and participate in discussions around increasing medical device development for children. More info here: https://go.usa.gov/xUvZm  #Pediatrics #medicaldevice pic.twitter.com/c0cuVYtTLK

FDA - U.S. Food and Drug Administration

27-7-2018

EU/3/14/1410 (Chiesi Farmaceutici S.p.A.)

EU/3/14/1410 (Chiesi Farmaceutici S.p.A.)

EU/3/14/1410 (Active substance: Recombinant human aspartylglucosaminidase) - Transfer of orphan designation - Commission Decision (2018)5051 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/172/14/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/15/1473 (Celgene Europe B.V.)

EU/3/15/1473 (Celgene Europe B.V.)

EU/3/15/1473 (Active substance: Lenalidomide) - Transfer of orphan designation - Commission Decision (2018)5042 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/284/14/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/14/1263 (bluebird bio (Germany) GmbH)

EU/3/14/1263 (bluebird bio (Germany) GmbH)

EU/3/14/1263 (Active substance: Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) - Transfer of orphan designation - Commission Decision (2018)5035 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/184/13/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/14/1295 (Celgene Europe B.V.)

EU/3/14/1295 (Celgene Europe B.V.)

EU/3/14/1295 (Active substance: Marizomib) - Transfer of orphan designation - Commission Decision (2018)5063 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/035/14/T/02

Europe -DG Health and Food Safety

19-7-2018

 Minutes of the CAT meeting 14-16 March 2018

Minutes of the CAT meeting 14-16 March 2018

Europe - EMA - European Medicines Agency

17-7-2018

Attivazione nuova piattaforma "OsSC" e progetto “Fast Track” (17/07/2018)

Attivazione nuova piattaforma "OsSC" e progetto “Fast Track” (17/07/2018)

L’Agenzia Italiana del Farmaco comunica l’attivazione della nuova versione dell’Osservatorio sulle Sperimentazioni Cliniche (OsSC), che sarà operativa a partire dal 18 luglio 2018 alle ore 14:00. La nuova versione sarà accessibile al link https://servizionline.aifa.gov.it/, dove apparirà nella sezione “Servizi in Single Sign-On” una voce “Osservatorio sulla sperimentazione clinica - OsSC”, con le utenze già attive con la precedente versione.

Italia - AIFA - Agenzia Italiana del Farmaco

9-7-2018

 Minutes of the PRAC meeting 14-17 May 2018

Minutes of the PRAC meeting 14-17 May 2018

Europe - EMA - European Medicines Agency

3-7-2018

The Pediatric Medical Device Development public meeting is August 13-14 at #FDA White Oak Campus. Do you know how the FDA defines “pediatrics” for medical device purposes? Click the link for the answer and more info on #Pediatric #MedicalDevices  https://

The Pediatric Medical Device Development public meeting is August 13-14 at #FDA White Oak Campus. Do you know how the FDA defines “pediatrics” for medical device purposes? Click the link for the answer and more info on #Pediatric #MedicalDevices https://

The Pediatric Medical Device Development public meeting is August 13-14 at #FDA White Oak Campus. Do you know how the FDA defines “pediatrics” for medical device purposes? Click the link for the answer and more info on #Pediatric #MedicalDevices https://go.usa.gov/xU2e8 

FDA - U.S. Food and Drug Administration

28-6-2018

Procedimento di definizione del budget e del ripiano per l’anno 2017 (28/06/2018)

Procedimento di definizione del budget e del ripiano per l’anno 2017 (28/06/2018)

Si fa seguito alle comunicazioni del 25 maggio e del 14 giugno, e si conferma che per quanto riguarda i dati dell’anno 2017, tramite il Portale del monitoraggio e del controllo della spesa farmaceutica, AIFA  ha messo  a disposizione (https://www.agenziafarmaco.gov.it/aifarsf/login) per ciascun codice SIS i seguenti dati, aggiornati al 27-06-2018 a seguito del processo di verifica avviato il 25/05/2018.

Italia - AIFA - Agenzia Italiana del Farmaco

27-6-2018

EU/3/15/1460 (Eisai GmbH)

EU/3/15/1460 (Eisai GmbH)

EU/3/15/1460 (Active substance: Lenvatinib) - Transfer of orphan designation - Commission Decision (2018)4080 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/287/14/T/01

Europe -DG Health and Food Safety

19-6-2018

Aftovaxpur Doe (Merial)

Aftovaxpur Doe (Merial)

Aftovaxpur Doe (Active substance: purified, inactivated foot-and-mouth disease virus strains O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir, SAT2 Saudi Arabia) - Centralised - Renewal - Commission Decision (2018)3891 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2292/R/8

Europe -DG Health and Food Safety

15-6-2018

News and press releases:  Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2018

News and press releases: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2018

PRAC held public hearing on quinolone and fluoroquinolone antibiotics

Europe - EMA - European Medicines Agency

14-6-2018

Avvio del procedimento di definizione del budget e del ripiano per l’anno 2017 (14/06/2018)

Avvio del procedimento di definizione del budget e del ripiano per l’anno 2017 (14/06/2018)

Tenuto conto delle risposte pervenute e dei necessari tempi di elaborazione da parte di AIFA dei dati inviati dalle Aziende a seguito del comunicato dell’Agenzia del 25/05/2018, si informa che l’esposizione dei dati rettificati (spesa e budget 2017) è posticipata al 27/06/2018. I dati verranno resi disponibili tramite il Portale del monitoraggio e del controllo della spesa farmaceutica.

Italia - AIFA - Agenzia Italiana del Farmaco

14-6-2018

Incruse (Glaxo Group Ltd)

Incruse (Glaxo Group Ltd)

Incruse (Active substance: umeclidinium bromide) - Centralised - Yearly update - Commission Decision (2018)3855 of Thu, 14 Jun 2018

Europe -DG Health and Food Safety

14-6-2018

Kuvan (BioMarin International Limited)

Kuvan (BioMarin International Limited)

Kuvan (Active substance: sapropterin dihydrochloride) - Centralised - Yearly update - Commission Decision (2018)3859 of Thu, 14 Jun 2018

Europe -DG Health and Food Safety

14-6-2018

Fareston (Orion Corporation)

Fareston (Orion Corporation)

Fareston (Active substance: Toremifene) - Centralised - Yearly update - Commission Decision (2018)3857 of Thu, 14 Jun 2018

Europe -DG Health and Food Safety

14-6-2018

Emtricitabine/Tenofovir disoproxil Mylan (Mylan S.A.S.)

Emtricitabine/Tenofovir disoproxil Mylan (Mylan S.A.S.)

Emtricitabine/Tenofovir disoproxil Mylan (Active substance: emtricitabine / tenofovir disoproxil) - Centralised - 2-Monthly update - Commission Decision (2018)3854 of Thu, 14 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4050/IB/3/G

Europe -DG Health and Food Safety

14-6-2018

Commissione Tecnico Scientifica (CTS) (14/06/2018)

Commissione Tecnico Scientifica (CTS) (14/06/2018)

Esiti, per singoli uffici, dei lavori della riunione della Commissione Tecnico Scientifica (CTS) dell'Agenzia Italiana del Farmaco del 11-12-13 giugno 2018.

Italia - AIFA - Agenzia Italiana del Farmaco

11-6-2018

Agenda:  Agenda - PRAC draft agenda of meeting 11-14 June 2018

Agenda: Agenda - PRAC draft agenda of meeting 11-14 June 2018

Europe - EMA - European Medicines Agency

2-6-2018

EU/3/14/1350 (Novartis Europharm Limited)

EU/3/14/1350 (Novartis Europharm Limited)

EU/3/14/1350 (Active substance: Recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor) - Transfer of orphan designation - Commission Decision (2018)3630 of Sat, 02 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/107/14/T/01

Europe -DG Health and Food Safety

1-6-2018

News and press releases:  Two more EU Member States benefit from EU-US mutual recognition agreement for inspections

News and press releases: Two more EU Member States benefit from EU-US mutual recognition agreement for inspections

Agreement now operational between 14 EU Member States and FDA

Europe - EMA - European Medicines Agency

29-5-2018

EU/3/14/1400 (Orphan Europe S.A.R.L.)

EU/3/14/1400 (Orphan Europe S.A.R.L.)

EU/3/14/1400 (Active substance: (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine) - Transfer of orphan designation - Commission Decision (2018)3402 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/185/14/T/01

Europe -DG Health and Food Safety

29-5-2018

EU/3/15/1453 (Roche Registration GmbH)

EU/3/15/1453 (Roche Registration GmbH)

EU/3/15/1453 (Active substance: Chimeric 2'-O-(2-methoxyethyl) modified oligonucleotide targeted to huntingtin RNA) - Transfer of orphan designation - Commission Decision (2018)3401 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/256/14/T/01

Europe -DG Health and Food Safety

24-5-2018

Regulatory and procedural guideline:  EudraVigilance release notes v.1.14

Regulatory and procedural guideline: EudraVigilance release notes v.1.14

This document lists and briefly describes the following areas for the releases of EVWEB starting with the release on 22 November 2017.

Europe - EMA - European Medicines Agency

21-5-2018

EU/3/14/1353 (Lupin Europe GmbH)

EU/3/14/1353 (Lupin Europe GmbH)

EU/3/14/1353 (Active substance: Mexiletine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)3134 of Mon, 21 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/074/14/T/03

Europe -DG Health and Food Safety

21-5-2018

EU/3/07/522 (Best Regulatory Consulting Ltd)

EU/3/07/522 (Best Regulatory Consulting Ltd)

EU/3/07/522 (Active substance: (manganese, dichloro [(4aR, 13aR, 17aR, 21aR)-1, 2, 3, 4, 4a, 5, 6, 12, 13, 13a, 14, 15, 16, 17, 17a, 18, 19, 20, 21, 21a-eicosahydro-11, 7-nitrilo-7H-dibenzo[ b,h] [1,4,7,10] tetraazacycloheptadecine-?N5, ?N13, ?N18, ?N21, ?N22]-)) - Transfer of orphan designation - Commission Decision (2018)3136 of Mon, 21 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/089/07/T/01

Europe -DG Health and Food Safety

21-5-2018

EU/3/14/1421 (Incyte Biosciences Distribution B.V.)

EU/3/14/1421 (Incyte Biosciences Distribution B.V.)

EU/3/14/1421 (Active substance: Ponatinib hydrochloride) - Transfer of orphan designation - Commission Decision (2018)3141 of Mon, 21 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/212/14/T/02

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1328 (Roche Registration GmbH)

EU/3/14/1328 (Roche Registration GmbH)

EU/3/14/1328 (Active substance: 4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid) - Transfer of orphan designation - Commission Decision (2018)3149 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/14/T/01

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1306 (Chiesi Farmaceutici S.p.A.)

EU/3/14/1306 (Chiesi Farmaceutici S.p.A.)

EU/3/14/1306 (Active substance: Cysteamine bitartrate) - Transfer of orphan designation - Commission Decision (2018)3151 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/070/14/T/01

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1252 (Chiesi Farmaceutici S.p.A.)

EU/3/14/1252 (Chiesi Farmaceutici S.p.A.)

EU/3/14/1252 (Active substance: Cysteamine bitartrate) - Transfer of orphan designation - Commission Decision (2018)3133 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/164/13/T/01

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1383 (IQVIA RDS Ireland Limited)

EU/3/14/1383 (IQVIA RDS Ireland Limited)

EU/3/14/1383 (Active substance: Single-chain urokinase plasminogen activator) - Transfer of orphan designation - Commission Decision (2018)3150 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/125/14/T/01

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1266 (Novartis Europharm Limited)

EU/3/14/1266 (Novartis Europharm Limited)

EU/3/14/1266 (Active substance: Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19) - Transfer of orphan designation - Commission Decision (2018)3145 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/187/13/T/01

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1298 (Genzyme Europe B.V.)

EU/3/14/1298 (Genzyme Europe B.V.)

EU/3/14/1298 (Active substance: Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues) - Transfer of orphan designation - Commission Decision (2018)3148 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/041/14/T/01

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1297 (Genzyme Europe B.V.)

EU/3/14/1297 (Genzyme Europe B.V.)

EU/3/14/1297 (Active substance: Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues) - Transfer of orphan designation - Commission Decision (2018)3147 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/039/14/T/01

Europe -DG Health and Food Safety

18-5-2018

News and press releases:  Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 14-17 May 2018

News and press releases: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 14-17 May 2018

PRAC concludes two referrals, maintains recommendation on HES solutions for infusion and issues precautionary advice on HIV medicine

Europe - EMA - European Medicines Agency